BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blumenthal DT, Mendel L, Bokstein F. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter? J Neurooncol 2016;127:493-502. [PMID: 26721244 DOI: 10.1007/s11060-015-2025-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lyon KA, Huang JH. Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts. Transl Cancer Res 2018;7:S802-5. [PMID: 30370226 DOI: 10.21037/tcr.2018.08.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Fisher JP, Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines 2021;9:324. [PMID: 33810154 DOI: 10.3390/biomedicines9030324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
3 Gleeson JP, Keane F, Keegan NM, Mammadov E, Harrold E, Alhusaini A, Harte J, Eakin-Love A, O'Halloran PJ, MacNally S, Hennessy BT, Breathnach OS, Grogan L, Morris PG. Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma. Cancer Med 2020;9:469-75. [PMID: 31756059 DOI: 10.1002/cam4.2616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zalles M, Smith N, Saunders D, Guzman M, Lerner M, Fung KM, Babu A, Battiste J, Chung J, Hwang K, Jin J, Towner RA. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies. Neurooncol Adv 2021;3:vdab132. [PMID: 34704036 DOI: 10.1093/noajnl/vdab132] [Reference Citation Analysis]
5 Sirven-villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, Paquis P, Burel-vandenbos F, Frenay M, Thomas P, Lebrun-frenay C. Bevacizumab: Is the lower the better for glioblastoma patients in progression? Bulletin du Cancer 2018;105:1135-46. [DOI: 10.1016/j.bulcan.2018.07.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
6 Zalles M, Smith N, Saunders D, Lerner M, Fung KM, Battiste J, Towner RA. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007. J Cell Mol Med 2021. [PMID: 34910361 DOI: 10.1111/jcmm.17133] [Reference Citation Analysis]
7 Chen Y, Guo L, Li X, Liu R, Ren C, Du S. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis. Clin Neurol Neurosurg 2020;198:106239. [PMID: 33007724 DOI: 10.1016/j.clineuro.2020.106239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L. Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 2017;135:99-105. [PMID: 28667595 DOI: 10.1007/s11060-017-2553-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]